Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Heather L Flick"'
Autor:
Marc S Ernstoff, Jan L Fisher, Jared E Lopes, Heather L Flick, Chunhua Wang, Lei Sun, Juan C Alvarez, Heather C Losey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Interleukin-2 (IL-2) plays a pivotal role in immune homeostasis due to its ability to stimulate numerous lymphocyte subsets including natural killer (NK) cells, effector CD4+ and CD8+ T cells, and regulatory T cells (Tregs). Low concentrat
Externí odkaz:
https://doaj.org/article/45f0eb598bd6444ebc023bb0ce491ca9
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 379:203-210
Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel cytokine created by the fusion of circularly permuted interleukin-2 (IL-2) to the IL-2Rα subunit of the IL-2 receptor (IL-2R) complex that confers selectivity for the intermediate-affinity IL-2R e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b501d2d3f4ee59904207fb6219c8c2a
https://doi.org/10.1124/jpet.121.000612
https://doi.org/10.1124/jpet.121.000612
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::6c9f64ea594454da097f3cbf41303f9f
https://jitc.bmj.com/content/8/1/e000157corr1.full
https://jitc.bmj.com/content/8/1/e000157corr1.full
Autor:
Lei Sun, Heather L. Flick, Juan Alvarez, Heather C. Losey, Rosemarie A. Moroso, Jared E. Lopes, Reginald L. Dean, Michael R. Huff
Publikováno v:
Cancer Research. 77:2663-2663
ALKS 4230 is a selective agonist of the intermediate-affinity IL-2 receptor (IL-2R). A phase 1 study is ongoing to evaluate the safety and tolerability of ALKS 4230 in the treatment of patients with refractory solid tumors. The selectivity of ALKS 42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99bddf652d7e188ab1c62a852d6f1ce5
https://doi.org/10.1158/1538-7445.am2017-2663
https://doi.org/10.1158/1538-7445.am2017-2663
Autor:
Rosemarie A. Moroso, Jared E. Lopes, Reginald L. Dean, Chunhua Wang, Madison Gomes, Julie F. Waters, Heather L. Flick, Heather C. Losey, Lei Sun, Michael R. Huff, Juan C. Alvarez
Publikováno v:
Cancer Research. 75:4280-4280
RDB 1450 is an engineered fusion protein which selectively activates the intermediate-affinity IL-2 receptor present on NK cells and memory CD8 T cells. In rodents, RDB 1450 has a half-life of 6-8 hours, compared to a half-life of minutes for recombi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1b674357c724e5268a74d76e0ced18c
https://doi.org/10.1158/1538-7445.am2015-4280
https://doi.org/10.1158/1538-7445.am2015-4280
Autor:
Juan C. Alvarez, Heather L. Flick, Heather C. Losey, Chunhua Wang, Emily E. Rosentrater, Jared E. Lopes
Publikováno v:
Cancer Research. 75:4281-4281
RDB 1450 is an engineered fusion protein designed to selectively activate the intermediate-affinity IL-2 receptor versus the high-affinity IL-2 receptor. The potencies of RDB 1450 and IL-2 for activation of distinct subsets of effector and regulatory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38452fddca840679c979d61323e595b7
https://doi.org/10.1158/1538-7445.am2015-4281
https://doi.org/10.1158/1538-7445.am2015-4281